Tesamorelin – GHRH Analog Research-5mg

$39.00

Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH), consisting of a stabilized sequence that promotes pulsatile release of growth hormone through pituitary stimulation. By engaging the GH–IGF-1 axis, Tesamorelin has been widely studied in the context of visceral fat metabolism, tissue regulation, and metabolic biomarkers, making it a valuable subject in experimental metabolic and aging-related research.

SKU: PPT-HK-50-880015
Products specifications
SPEC
5mg
FORM
Lyophilized powder
PRICE BREAKS - The more you buy, the more you save
Quantity 1+ 10+
Price $39.00 $33.00

1. What is Tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH), consisting of a stabilized sequence that promotes pulsatile release of growth hormone through pituitary stimulation. By engaging the GH–IGF-1 axis, Tesamorelin has been widely studied in the context of visceral fat metabolism, tissue regulation, and metabolic biomarkers, making it a valuable subject in experimental metabolic and aging-related research.


2. Tesamorelin Structure

Molecular FormulaC₂₂₁H₃₆₆N₇₂O₆₇S

Molecular Weight5,136 g/mol

CAS Number218949‑48‑5

 


3. Tesamorelin Research

1Core Mechanisms

Visceral fat regulation: Stimulates GH pathways, catalyzing fat breakdown in central adipose tissue.

IGF-1 activation: Supports natural increases in IGF-1, a downstream mediator of cellular repair and anabolic activity 1.

Tissue density effects: Linked with improvements in muscle density and fat quality, suggesting healthier body composition 2.

Metabolic pathway impact: Associated with favorable changes in adipokines such as adiponectin, triglyceride reduction, and systemic inflammatory markers.

2Research & Clinical Evidence

Visceral fat reduction: Controlled studies have shown significant reductions in visceral adipose tissue (VAT) over 26 weeks 3.

Liver fat & NAFLD: Observations indicate decreased hepatic fat accumulation in HIV-associated fatty liver models 4.

Muscle quality: CT imaging analyses reported enhanced trunk muscle area and density 5.

Metabolic biomarkers: Improvements in triglycerides and adiponectin levels suggest metabolic health benefits 6.


Why Consider Tesamorelin?

Targeted fat studies: Strong evidence in visceral fat reduction while sparing lean tissue.

IGF-1 axis engagement: Provides a natural route for studying anabolic and regenerative pathways.

Metabolic outcomes: Associated with lipid improvements, adiponectin elevation, and reduced inflammatory signals.

Body composition research: Supports lean mass and muscle density in imaging-based studies.

Multi-cohort validation: Results reproduced across different antiretroviral therapy backgrounds.

Academic interest: Extensively studied in leading metabolic research groups 7.


4. Future Tesamorelin Research

·  Expanded populations: Exploring potential roles in non-HIV obesity, metabolic syndrome, and age-related abdominal fat 8.

·  Exercise & strength outcomes: Studying synergy with physical activity for mobility and frailty research 9.

·  Cardiovascular biomarkers: Pilot trials suggest improvements in vascular inflammation and cIMT.

·  Liver applications: Further studies needed in NAFLD/NASH cohorts for long-term hepatic support.

·  Formulation improvements: Investigation into depot injections, weekly regimens, and advanced carriers for better compliance.

·  Biomarker discovery: Identification of IGF-1 thresholds, adiponectin shifts, and inflammatory markers to refine personalized approaches.


5. Application Areas

Use Case

Research Insights

Visceral fat studies

Reduction of central adiposity and improved fat density

Metabolic health models

Triglyceride lowering, adipokine shifts, inflammatory marker modulation

Liver metabolism

Evidence for decreased hepatic steatosis in early studies

Muscle composition

Improved trunk muscle quality and density

Exercise & aging

Explored for functional strength and recovery when paired with activity

Cardiovascular research

Studied for risk modulation via fat and inflammatory pathways


Summary

Tesamorelin is a research peptide analogue of GHRH that has been extensively investigated for its effects on visceral fat reduction, IGF-1 modulation, metabolic biomarkers, and muscle density. With evidence from multiple controlled trials, it stands out as a valuable tool in metabolic, hepatic, and aging-related research models. Ongoing studies continue to expand its potential applications across broader populations and biomarker-driven protocols.


Disclaimer

 

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished
for in-vitro studies only. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

Only registered users can write reviews